Curated CRC research, accessible, accurate, actionable

The CRC Digest

Wednesday, September 23, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◆ TRIAL DATA

  Ifebemtinib Plus Garsorasib in KRAS G12C–Mutated Metastatic Colorectal Cancer

  (Oncodaily)

• ● REGULATORY

  German S3 Guidelines Recommend MMR/MSI Testing Before Treatment Initiation

  Updated German S3 guidelines on colorectal cancer now recommend determination of mismatch repair deficiency/microsatellite instability status before initiation of treatment, which can fundamentally alter treatment strategy, particularly in rectal cancer. (Chirurgie)

• ▪ SCREENING

  Multiple Rounds of Fecal Hemoglobin Testing Improve Colorectal Cancer Risk Prediction

  Analysis of Dutch national screening data found that incorporating faecal haemoglobin concentrations from three prior screening rounds improves risk stratification for colorectal cancer and advanced neoplasia beyond single-round testing. (BMJ Open Gastroenterology)

• ▪ SCREENING

  Screening Colonoscopy Safe and Effective in Adults 75 and Older

  A retrospective Korean study of 602 patients aged 75 and older found high cecal intubation success and detection rates of 10.5%, 6.8%, and 0.9% for non-advanced adenoma, advanced adenoma, and colorectal cancer, respectively. (Clinical Endoscopy)

• ▸ TREATMENT

  Meta-Analysis Quantifies Toxicity Profile of Fruquintinib in GI Malignancies

  A systematic review and meta-analysis of phase II–III randomized trials synthesized evidence on the incidence and relative risk of key toxicities associated with fruquintinib, a VEGFR inhibitor approved for metastatic colorectal cancer. (Oncology Research)

This week's research reflects ongoing efforts to refine screening strategies, integrate molecular testing into treatment planning, and understand the biological drivers of early-onset disease.